NDAORALCAPSULE
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
21
Mechanism of Action
Rearranged during Transfection (RET) Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Started Jul 2024
13 enrolled
Differentiated Thyroid CancerPediatric CancerCancer+1 more
A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants
Started Jul 2023
28 enrolled
Healthy
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Started Mar 2023
30 enrolled
Thyroid CancerThyroid CarcinomaMetastatic Thyroid Cancer+3 more
A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants
Started Apr 2022
46 enrolled
Healthy
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Started Dec 2021
152 enrolled
Carcinoma, Non-Small-Cell Lung
Loss of Exclusivity
LOE Date
Apr 10, 2039
159 months away
Patent Expiry
Apr 10, 2039
Exclusivity Expiry
Nov 29, 2031
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 10112942 | Oct 10, 2037 | SubstanceProduct | — |
| 10137124 | Oct 10, 2037 | U-3951 | |
| 10172851 | Oct 10, 2037 | U-3950 | |
| 10137124*PED | Apr 10, 2038 | — | |
| 10172851*PED | Apr 10, 2038 | — |